Plate Nº 54 · recorded November 17, 2026

Health & Medicine ResearchReported finding

Capsule of 16 Live Bacteria May Cut Infections After Stem Cell Transplants

An experimental capsule of 16 selected bacteria reduced bloodstream infections in stem cell transplant patients in an early safety trial. Larger studies must confirm the effect.

By James Calloway3 min read584 words

In brief

  1. SER-155 contains 16 kinds of bacteria selected to compete with harmful microbes
  2. An early trial in Nature Medicine found fewer bloodstream infections in treated patients
  3. Researchers reported no treatment-related side effects
  4. Trial run by City of Hope, Memorial Sloan Kettering and Seres Therapeutics
A capsule of live bacteria may prevent infections after stem cell transplants
Plate Nº 54A capsule of live bacteria may prevent infections after stem cell transplants — PublicDomainPictures / pixabay

An experimental capsule carrying 16 kinds of live bacteria reduced bloodstream infections in stem cell transplant patients in an early trial. The results, published in Nature Medicine, are preliminary — a safety study, not proof — but they point toward a new way to protect patients whose immune systems are at their weakest.

The treatment, called SER-155, aims at a familiar problem in transplant medicine. Donor stem cell transplants can treat some blood cancers, yet the preparation and recovery disrupt the gut microbiome — the community of microbes living in the digestive tract. When protective bacteria disappear, harmful ones multiply. And if those bacteria cross into the gut's lining into the bloodstream, patients have few defenses left to stop them.

How is the treatment supposed to work?

The researchers did not pick their bacteria at random. They selected types that could compete with harmful microbes for food, produce substances that limit those microbes' growth, or influence the immune response directly. In plain terms: the capsule reseeds the gut with organisms that crowd out the troublemakers.

The study's procedure had two steps. Patients first received an antibiotic to clear space so the introduced bacteria could take hold. They then swallowed the capsules, starting before the transplant and taking another course afterward.

The team tracked whether the bacteria actually established themselves. They found signs that the introduced organisms did colonize the gut, especially after the second course. Treated patients also carried lower levels of some potentially harmful bacteria.

What did the infection numbers show?

Fewer bloodstream infections turned up in the treated group. That sounds like the headline finding, and it is — but here's the caveat the investigators themselves stress. This was an early safety study. It was built to establish that the treatment is tolerable and biologically active, not to measure precisely how much protection it provides. A larger trial is needed before anyone can quote a reliable reduction in infection risk.

The safety data, at least, came back clean. Giving live bacteria to people with weakened immune systems is itself a legitimate safety question, since the therapy introduces organisms into bodies that cannot easily fight anything off. The researchers reported no treatment-related side effects. Still, small trials miss rare problems. A larger study could reveal harms that this limited group of patients would be unlikely to show.

What does this change for patients?

Right now, almost nothing. The capsules are experimental. Seres Therapeutics, the study's sponsor, and its partners — City of Hope and Memorial Sloan Kettering Cancer Center — will need to confirm that the results hold across different transplant centers and across patients with different treatment histories. Single-center effects sometimes fade when a therapy travels.

One warning worth printing in bold: this is not a license to buy probiotics off the shelf. The SER-155 capsules contain a carefully selected, defined set of bacteria. Products sold as probiotics can contain quite different organisms, and the findings here simply cannot be transferred to whatever sits in the supplement aisle.

Where does this fit in infection care?

Antibiotics remain central to preventing and treating infections during transplant care, and nothing in this study challenges that. The idea behind SER-155 is to work a different angle: rebuilding the gut's natural defenses that normally keep unwanted bacteria in check, rather than killing microbes after the fact.

The next test is whether that approach can consistently prevent serious infections without creating new risks. The promise is real. The evidence, so far, is early.

via knowridge.com (Source)

Filed under

  • ser-155
  • stem-cell-transplants
  • gut-microbiome
  • live-bacteria-therapy
  • bloodstream-infections
Share this article:

More from James Calloway

James Calloway

Show full bio

Staff writer covering regulation, policy and their impact on general science news at SciBeat.

474 articles

Nearby plates

« Previous articleNext article »